ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0102

Bone Health in Patients with Psoriatic Arthritis in the National Swiss Cohort: A Cross-sectional Study

Diana Camelia Dan1, Youssef Ibrahimy2, Berengere Aubry-Rozier3 and Daniel Aeberli4, 1Lausanne University Hospital, Lausanne, Switzerland, 2University of Lausanne, Lausanne, Switzerland, 3Hôpital orthopédique, Lausanne, Switzerland, 4University Hospital of Bern, Bern, Switzerland

Meeting: ACR Convergence 2020

Keywords: Fracture, osteoporosis, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Osteoporosis & Metabolic Bone Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: There is much controversy surrounding the loss of bone mass in patients with psoriasis arthritis (PsA). We wanted to evaluate the prevalence of osteoporosis (OP) and fracture in patients with PsA in the Swiss Clinical Quality Management (SCQM) cohort, a large national database of patients with inflammatory arthritis; to study different factors influencing bone health and the correlation between disease activity, treatment and occurrence of densitometric osteoporosis or fracture.

Methods: We analyzed all PsA-patients included in the cohort from 2006 to April 2019. We evaluated demographic and clinical data: age, gender, BMI, disease duration, smoking/alcohol habits, patient’s and physician’s global assessment, joint count, HAQ, medication and inflammatory activity measured by ESR, CRP, DAS 28 and DAPSA score. We compared patients with BMD measurement (DXA) with the group without DXA (nDXA). In DXA group we analyzed patients according to osteoporotic status and did subgroup analysis in premenopausal, menopausal women and men. We used STATA program vs 16, chi2-test, student’s t-test and simple and multiple regression models for statistics. Statistical significance was set up at p < 0.05.

Results: Of the 2443 patients, 545 had a DXA. The age of scanned patients was 18-84 years. Only 295 BMD data were available for analysis. DXA patients were 6.4 years older (54.2±11,1 vs 47.8±12.4 years, p< 0.001), and were more female (67% vs 43%). Duration of the disease was longer (6.6±8.3 vs 5.3±7.1 y, p< 0.001) in the DXA group. DAS28-CRP and DAS28-ESR were higher in DXA group (3,1 ± 1,2 vs 2,9 ± 1,1, p< 0,04 and 3,2 ± 1,4 vs 3 ± 1,3, p< 0,002, respectively), as was the DAPSA score (32 ± 30 vs 27 ± 20 p< 0.04). Patients in DXA group were more exposed to prednisone and conventional DMARDs (15.4% vs 4.7%, p< 0.001 and 51.7% vs 43%, p< 0.01 respectively). There were more fractures in the DXA- than in nDXA-group (5.7% vs 1.4%, P< 0.001) (Figure 1).

In the DXA group 18.4% patients had OP and 50.2% osteopenia. Patient characteristics are shown in Table 1. We confirmed a positive correlation between femoral and lumbar T-score and BMI, and negative correlation between age and femoral T-score. Disease duration was inversely correlated with femoral, but not lumbar T-score. Interestingly, other variables, including disease activity, showed no correlation with T-score, but OP patients had higher disease activity.

Subgroup analysis (Figure 2) showed higher OP prevalence in postmenopausal women (22,6%) vs in men (16.8%) or premenopausal women (10.7%) in concordance with the fracture rate (8.3% vs 6.3% vs 3.9%). T-score was lower and the disease activity was higher in postmenopausal women compared to the others groups.

Conclusion: Our data suggest that Swiss clinician are aware of risk of poor bone-health in PsA patients and perform DXA in this population even in younger patients and in men. Interestingly, we describe that the patients with OP had higher disease activity and poorer functional status than patients without OP. 

Longitudinal studies are needed to evaluate bone quality, fractures, and relationship between bone health in PsA and disease associated factors. They should integrate parameters of bone turnover and use an appropriate control group.


Disclosure: D. Dan, None; Y. Ibrahimy, None; B. Aubry-Rozier, None; D. Aeberli, None.

To cite this abstract in AMA style:

Dan D, Ibrahimy Y, Aubry-Rozier B, Aeberli D. Bone Health in Patients with Psoriatic Arthritis in the National Swiss Cohort: A Cross-sectional Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/bone-health-in-patients-with-psoriatic-arthritis-in-the-national-swiss-cohort-a-cross-sectional-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bone-health-in-patients-with-psoriatic-arthritis-in-the-national-swiss-cohort-a-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology